AIM/HYPOTHESIS: We examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy. METHODS: Transgenic (mRen-2)27 rats, which overexpress mouse renin and angiotensin in extra-renal tissues, were studied. For diabetic studies, non-diabetic, diabetic (streptozotocin, 55 mg/kg), diabetic + aliskiren (10 mg kg(-1) day(-1), pump), or diabetic + lisinopril (10 mg kg(-1) day(-1), drinking water) rats were evaluated over 16 weeks. For oxygen-induced retinopathy studies, rats were exposed to 80% oxygen (22 h/day) from postnatal days 0 to 11, and then room air from postnatal days 12 to 18. Aliskiren (10 or 30 mg kg(-1) day(-1), pump) or lisinopril (10 mg kg(-1) day(-1), drinking water) was administered during retinopathy development between postnatal days 12 and 18. RESULTS: Systolic BP in diabetic (mRen-2)27 rats was reduced with 10 mg kg(-1) day(-1) aliskiren, but only lisinopril normalised systolic blood pressure. In diabetic (mRen-2)27 rats, 10 mg kg(-1) day(-1) aliskiren and lisinopril reduced retinal acellular capillaries and leucostasis to non-diabetic levels. In oxygen-induced retinopathy, neoangiogenesis and retinal inflammation (leucostasis, ED-1 immunolabelling) were partially reduced by 10 mg kg(-1) day(-1) aliskiren and normalised by 30 mg kg(-1) day(-1) aliskiren, whereas lisinopril normalised neoangiogenesis and reduced leucostasis and ED-1 immunolabelling. Aliskiren and lisinopril normalised retinal vascular endothelial growth factor expression; however, only aliskiren reduced intercellular adhesion molecule-1 to control levels. CONCLUSIONS/ INTERPRETATION: Aliskiren provided similar or greater retinal protection than ACE inhibition and may be a potential treatment for diabetic retinopathy.
AIM/HYPOTHESIS: We examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy. METHODS: Transgenic (mRen-2)27 rats, which overexpress mouserenin and angiotensin in extra-renal tissues, were studied. For diabetic studies, non-diabetic, diabetic (streptozotocin, 55 mg/kg), diabetic + aliskiren (10 mg kg(-1) day(-1), pump), or diabetic + lisinopril (10 mg kg(-1) day(-1), drinking water) rats were evaluated over 16 weeks. For oxygen-induced retinopathy studies, rats were exposed to 80% oxygen (22 h/day) from postnatal days 0 to 11, and then room air from postnatal days 12 to 18. Aliskiren (10 or 30 mg kg(-1) day(-1), pump) or lisinopril (10 mg kg(-1) day(-1), drinking water) was administered during retinopathy development between postnatal days 12 and 18. RESULTS: Systolic BP in diabetic (mRen-2)27 rats was reduced with 10 mg kg(-1) day(-1) aliskiren, but only lisinopril normalised systolic blood pressure. In diabetic (mRen-2)27 rats, 10 mg kg(-1) day(-1) aliskiren and lisinopril reduced retinal acellular capillaries and leucostasis to non-diabetic levels. In oxygen-induced retinopathy, neoangiogenesis and retinal inflammation (leucostasis, ED-1 immunolabelling) were partially reduced by 10 mg kg(-1) day(-1) aliskiren and normalised by 30 mg kg(-1) day(-1) aliskiren, whereas lisinopril normalised neoangiogenesis and reduced leucostasis and ED-1 immunolabelling. Aliskiren and lisinopril normalised retinal vascular endothelial growth factor expression; however, only aliskiren reduced intercellular adhesion molecule-1 to control levels. CONCLUSIONS/ INTERPRETATION:Aliskiren provided similar or greater retinal protection than ACE inhibition and may be a potential treatment for diabetic retinopathy.
Authors: Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman Journal: Diabetes Date: 2007-02 Impact factor: 9.461
Authors: Laura E Downie; Kate M Hatzopoulos; Michael J Pianta; Algis J Vingrys; Jennifer L Wilkinson-Berka; Michael Kalloniatis; Erica L Fletcher Journal: J Comp Neurol Date: 2010-01-01 Impact factor: 3.215
Authors: Erica L Fletcher; Joanna A Phipps; Michelle M Ward; Kirstan A Vessey; Jennifer L Wilkinson-Berka Journal: Prog Retin Eye Res Date: 2010-04-07 Impact factor: 21.198
Authors: C J Moravski; D J Kelly; M E Cooper; R E Gilbert; J F Bertram; S Shahinfar; S L Skinner; J L Wilkinson-Berka Journal: Hypertension Date: 2000-12 Impact factor: 10.190
Authors: Johannes Stegbauer; De-Hyung Lee; Silvia Seubert; Gisa Ellrichmann; Arndt Manzel; Heda Kvakan; Dominik N Muller; Stefanie Gaupp; Lars Christian Rump; Ralf Gold; Ralf A Linker Journal: Proc Natl Acad Sci U S A Date: 2009-08-19 Impact factor: 11.205
Authors: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: A H Danser; M A van den Dorpel; J Deinum; F H Derkx; A A Franken; E Peperkamp; P T de Jong; M A Schalekamp Journal: J Clin Endocrinol Metab Date: 1989-01 Impact factor: 5.958
Authors: Jennifer L Wilkinson-Berka; Devy Deliyanti; Indrajeetsinh Rana; Antonia G Miller; Alex Agrotis; Roksana Armani; Cédric Szyndralewiez; Kirstin Wingler; Rhian M Touyz; Mark E Cooper; Karin A Jandeleit-Dahm; Harald H H W Schmidt Journal: Antioxid Redox Signal Date: 2013-10-30 Impact factor: 8.401
Authors: Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: Wendy W Batenburg; Amrisha Verma; Yunyang Wang; Ping Zhu; Mieke van den Heuvel; Richard van Veghel; A H Jan Danser; Qiuhong Li Journal: PLoS One Date: 2014-06-26 Impact factor: 3.240
Authors: Tuhina Prasad; Lodi C W Roksnoer; Ping Zhu; Amrisha Verma; Yiming Li; Wendy W Batenburg; René de Vries; A H Jan Danser; Qiuhong Li Journal: Invest Ophthalmol Vis Sci Date: 2016-12-01 Impact factor: 4.799